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Abstract
Objective
To quantify the association between early neurologic recovery, practice pattern variation, and
endotracheal intubation during established status epilepticus, we performed a secondary
analysis within the cohort of patients enrolled in the Established Status Epilepticus Treatment
Trial (ESETT).
Methods
We evaluated factors associated with the endpoint of endotracheal intubation occurring within
120 minutes of ESETT study drug initiation. We deﬁned a blocked, stepwise multivariate
regression, examining 4 phases during status epilepticus management: (1) baseline characteristics, (2) acute treatment, (3) 20-minute neurologic recovery, and (4) 60-minute recovery,
including seizure cessation and improving responsiveness.
Results
Of 478 patients, 117 (24.5%) were intubated within 120 minutes. Among high-enrolling sites,
intubation rates ranged from 4% to 32% at pediatric sites and 19% to 39% at adult sites. Baseline
characteristics, including seizure precipitant, benzodiazepine dosing, and admission vital signs,
provided limited discrimination for predicting intubation (area under the curve [AUC] 0.63).
However, treatment at sites with an intubation rate in the highest (vs lowest) quartile strongly
predicted endotracheal intubation independently of other treatment variables (adjusted odds
ratio [aOR] 8.12, 95% conﬁdence interval [CI] 3.08–21.4, model AUC 0.70). Site-speciﬁc
variation was the factor most strongly associated with endotracheal intubation after adjustment
for 20-minute (aOR 23.4, 95% CI 6.99–78.3, model AUC 0.88) and 60-minute (aOR 14.7, 95%
CI 3.20–67.5, model AUC 0.98) neurologic recovery.
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Glossary
aOR = multivariate-adjusted odds ratio; CI = conﬁdence interval; ESETT = Established Status Epilepticus Treatment Trial;
FOS = fosphenytoin; ICU = intensive care unit; IQR = interquartile range; LEV = levetiracetam; SE = status epilepticus; VPA =
valproic acid.

Conclusions
Endotracheal intubation after established status epilepticus is strongly associated with site-speciﬁc practice pattern variation,
independently of baseline characteristics, and early neurologic recovery and should not alone serve as a clinical trial endpoint in
established status epilepticus.
Trial Registration Information
ClinicalTrials.gov Identiﬁer: NCT01960075.
Status epilepticus (SE) is a common neurologic emergency,1-5
requiring immediate intervention to avoid increasingly refractory seizures, cardiopulmonary complications, and the
potential for irreversible neuronal injury.6-8 While providers
may perform endotracheal intubation to induce anesthetic
coma and to facilitate deﬁnitive seizure control, intubation
may alternatively be performed to secure the airway for imaging, transport, and management of hypoxemia, hypoventilation, or loss of airway protective reﬂexes.9-11
Clinically, the concern for airway compromise may inﬂuence
practice patterns during SE management. First-line benzodiazepines are commonly underdosed,12 potentially due to perceived
risks of respiratory failure, despite risk being greatest among
untreated patients. In clinical trials, intubation remains an endpoint deﬁned as treatment failure,13-15 independently of its indication, in part because evaluating neurologic activity is
constrained by concomitant sedation or neuromuscular blockade. Accordingly, clinical trials aiming to develop new therapeutics to improve the early management of SE are challenging,
considering that intubation rates have nearly doubled over a
decade.16 In the recent Established Status Epilepticus Treatment
Trial (ESETT), second-line antiseizure medication yielded seizure cessation with improvement in consciousness in only 50%,
while 20% of ESETT patients failed the primary endpoint due to
undergoing intubation, regardless of the indication.17,18
We hypothesized that the risk of intubation is partially explained
by baseline patient factors and practice pattern variation, independently of posttreatment clinical and neurologic recovery.
We therefore performed a secondary analysis within the ESETT
cohort, examining 4 phases of established SE management: (1)
baseline patient characteristics, (2) acute treatment factors, (3)
20-minute recovery, and (4) 60-minute recovery.

Methods
Study Design and Setting
Details of the ESETT study design have previously been
published.18 In brief, patients ≥2 years of age with
Neurology.org/N

benzodiazepine-refractory convulsive SE were randomized
in a 1:1:1 ratio to a 10-minute infusion of fosphenytoin
(FOS) 20 mg/kg (maximum 1.5 g), levetiracetam (LEV)
60 mg/kg (maximum 4.5 g), or valproic acid (VPA) 40 mg/
kg (maximum 3 g). Presence or absence of seizure activity
was recorded at 20 and 60 minutes after initiation of the
investigational protocol, as was the presence or absence of
improving responsiveness. Enrollment was halted for futility after a preplanned interim analysis17 but later extended to evaluate the possibility of a most eﬀective
treatment in children18; we evaluated the ﬁnal overall cohort of 478 patients enrolled at 58 hospital emergency
departments across the United States between November
2015 and December 2018. Of 58 sites, 25 sites enrolled
only adults and 19 sites enrolled only children.18
Standard Protocol Approvals, Registrations,
and Patient Consents
Patients were enrolled under Exception From Informed
Consent for Emergency Research.19 The study was approved
by the Food and Drug Administration and institutional review
boards of all participating sites. ESETT was registered at
ClinicalTrials.gov (NCT01960075).
Candidate Risk Factors
We examined factors inﬂuencing the decision to intubate
patients with established SE available to clinicians during 4
phases of care: phase 1, baseline patient characteristics available at presentation and before study drug initiation; phase 2,
acute treatment factors, including study drug allocation and
site-speciﬁc risk of intubation, at each institution; phase 3, 20minute recovery (from time of study drug initiation); and
phase 4, 60-minute recovery.
Phase 1 baseline factors evaluated as candidate covariates
included demographic characteristics such as age, sex, race
and ethnicity, history of epilepsy, acute precipitant of SE,
baseline dose of ﬁrst-line benzodiazepine, calculated as total
weight-standardized lorazepam equivalents before study drug
initiation, the duration of seizures or SE before emergency
department arrival and enrollment, and standardized values of
Neurology | Volume 96, Number 19 | May 11, 2021
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Table 1 Patient Characteristics by Intubation Status (Performed or Attempted Within 120 Minutes)
Participants
(n = 478)

Not intubated
(n = 361, 75.5%)

Intubated
(n = 117, 24.5%)

OR (95% CI)

478

26.6 (24.8)

33.9 (26.4)

1.06 (1.02–1.10)

p Value

Phase 1: baseline patient characteristics
Age, mean (SD) (odds/5-y increase)
Age group, n (%)

0.05

<18 y (reference)

229

184 (80)

45 (20)

—

18–65 y

196

141 (72)

55 (28)

1.60 (1.02–2.50)

>65 y

53

36 (68)

17 (32)

1.93 (1.00–3.74)

271

205 (76)

66 (24)

0.98 (0.65–1.50)

Male sex, n (%)

0.007

Race, n (%)

0.94
0.03

Black

201

140 (70)

61 (30)

1.59 (1.02–2.48)

White (reference)

209

164 (78)

45 (21)

—

Other

68

57 (84)

11 (16)

0.70 (0.34–1.45)

Hispanic ethnicity, n (%)

77

66 (86)

11 (14)

0.46 (0.24–0.91)

0.03

History of epilepsy, n (%)

319

244 (76)

75 (24)

0.86 (0.55–1.33)

0.49

Acute precipitant, n (%)

0.03

Unprovoked (reference)

166

131 (79)

35 (21)

—

Febrile illness

94

70 (74)

24 (26)

1.28 (0.71–2.33)

Other

67

57 (85)

10 (15)

0.66 (0.30–1.42)

ASM nonadherence

62

50 (81)

12 (19)

0.90 (0.43–1.87)

Toxic

30

19 (63)

11 (37)

2.17 (0.94–4.97)

Idiopathic

21

14 (67)

7 (33)

1.87 (0.70–4.99)

Stroke/hemorrhage

17

9 (53)

8 (47)

3.33 (1.20–9.25)

CNS tumor

8

5 (62)

3 (38)

2.25 (0.51–9.86)

CNS infection

7

4 (57)

3 (43)

2.81 (0.60–13.13)

Metabolic abnormality

6

2 (33)

4 (67)

7.48 (1.32–42.53)

Baseline LZPE, median (IQR) (odds/0.1 mg/kg)

478

0.10 (0.06–0.18)

0.09 (0.06–0.16)

1.06 (0.85–1.32)

0.59

Onset-to-door time, median (IQR), min

434

38 (7–62)

39 (24–62)

1.00 (1.00–1.00)

0.47

Baseline systolic BP, |z score|, mean (SD)

452

0.75 (0.64)

0.78 (0.62)

1.08 (0.78–1.51)

0.64

Baseline diastolic BP, |z score|, mean (SD)

452

0.72 (0.62)

0.85 (0.68)

1.35 (0.98–1.85)

0.07

Baseline heart rate, |z score|, mean (SD)

466

1.58 (1.46)

1.38 (1.34)

0.90 (0.77–1.06)

0.21

Baseline respiratory rate, |z score|, mean (SD)

459

1.35 (1.83)

1.24 (1.88)

0.97 (0.85–1.10)

0.60

Baseline oxygen saturation, median (IQR)

463

99 (97–100)

99 (97–100)

0.97 (0.93–1.01)

0.09

Baseline temperature, median (IQR), °C

381

37 (36.6–37.8)

36.9 (36.6–37.9)

1.11 (0.90–1.37)

0.32

Patient weight, z score for age group, mean (SD)

478

0.00 (1.00)

−0.01 (0.99)

0.99 (0.80–1.22)

0.94

First quartile (low risk)

98

90 (92)

8 (8)

—

Second quartile

136

108 (79)

28 (21)

2.92 (1.27–6.72)

Phase 2: acute treatment factors
Site risk, n (%)
<0.0001

Continued
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Table 1 Patient Characteristics by Intubation Status (Performed or Attempted Within 120 Minutes) (continued)
Participants
(n = 478)

Not intubated
(n = 361, 75.5%)

Intubated
(n = 117, 24.5%)

OR (95% CI)

Third quartile

188

132 (70)

56 (30)

4.77 (2.17–10.5)

Fourth quartile (high risk)

56

31 (55)

25 (45)

9.07 (3.71–22.20)

478

15.8 (9.9)

15.2 (10.0)

0.99 (0.97–1.01)

0.57

LEV

180

139 (77)

41 (23)

1.17 (0.69–1.99)

0.08

FOS

149

103 (69)

46 (31)

1.77 (1.04–3.01)

VPA (reference)

149

119 (80)

30 (20)

—

478

28 (33)

23 (13)

0.99 (0.96–1.01)

0.39

Within 20 min

31

20 (65)

11 (35)

1.77 (0.82–3.81)

0.14

21–60 min

55

42 (76)

13 (24)

0.95 (0.49–1.84)

0.88

Within 20 min

7

5 (71)

2 (29)

1.24 (0.24–6.47)

0.68

21–60 min

38

30 (79)

8 (21)

0.81 (0.36–1.82)

0.61

160

85 (53)

75 (47)

3.90 (2.50–6.10)

<0.0001

216

209 (96)

8 (4)

0.07 (0.03–0.13)

<0.0001

11

5 (46)

6 (54)

4.30 (1.29–14.4)

0.02

139

31 (22)

108 (78)

2.00 (1.06–3.78)

0.03

278

273 (98)

5 (2)

0.03 (0.02–0.05)

<0.0001

Site enrollment volume, mean (SD)

p Value

Study drug, n (%)

Door-to-drug time, median (IQR) (odds/10 minutes), min
Additional BZD,a n (%)

Additional ASM,a n (%)

Phase 3: 20-min recovery
Clinically apparent seizure at 20 min,a n (%)
a

Improving responsiveness at 20 min, n (%)
a

Hypotension or arrhythmia, within 120 min, n (%)
Phase 4: 60-min recovery
Clinically apparent seizures at 60 min,a n (%)
a

Improving responsiveness at 60 min, n (%)

Abbreviations: ASM = antiseizure medication; BP = blood pressure; BZD = benzodiazepine; CI = confidence interval; FOS = fosphenytoin; IQR = interquartile
range; LEV = levetiracetam; LZPE = lorazepam equivalents; OR = odds ratio; VPA = valproic acid; || = absolute value.
a
Preintubation.

individual baseline vital signs. The z scores for heart rate,
respiratory rate, and weight were derived by standardizing
those values with the means and SDs of each participant’s age
cohort. While weight standardized by age was included, height
was not reliably ascertained in the emergency setting, and
accordingly, body mass index was not available as a covariate.
Blood pressure was standardized on the basis of the participant’s age and sex cohorts. Given that both high and low
blood pressure and respiratory rates have been associated with
severity in other emergency conditions,20 we evaluated statistical diﬀerences in these parameters as the absolute value of
the z score while examining for associations between endotracheal intubation and individual or multiple vital signs in
exploratory analyses. Because all patients in this cohort presented with generalized convulsive seizures and because coma
and arousal were not reassessed until after treatment in this
time-sensitive clinical trial, these components of the Status
Epilepticus Severity Score21 were similar for the patients
Neurology.org/N

included in the study. The remaining subscore elements (age
and seizure history) were thus examined as individual covariates. Data suﬃcient to reconstruct pediatric severity scores22
were not recorded in this cohort.
Phase 2 treatment factors evaluated as candidate covariates
were site-speciﬁc intubation risk; intention-to-treat allocation
to FOS, LEV, or VPA as the second-line agent study drug; and
additional antiseizure medications administered within 30
minutes of second-line agent initiation. To avoid conﬂating
benzodiazepines administered for seizure control with those
administered for anesthetic induction before intubation, we
excluded benzodiazepines administered either within 5 minutes of intubation or within 5 minutes of an anesthetic
(propofol, ketamine, or etomidate) or midazolam administered after initial ﬁrst-line therapy used an alternative benzodiazepine agent (i.e., midazolam after initial use of
lorazepam or diazepam). Site-speciﬁc intubation risk was
Neurology | Volume 96, Number 19 | May 11, 2021
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deﬁned by ranking sites (quartiles) based on the site-speciﬁc
proportion of patients undergoing intubation during the initial 120 minutes (calculated via posterior β distribution given
a prior β distribution [0.25, 0.75]); this variable was in addition ascertained in a funnel plot for outliers beyond the 95%
and 99% conﬁdence intervals (CIs) for site intubation risk
expected for the site-speciﬁc enrollment volume at each site
and risk for the association between patient age, site-speciﬁc
intubation risk, and site type (pediatric emergency department, adult emergency department, or general emergency
department).
Phase 3 early treatment response candidate covariates included the presence of clinically apparent seizures at 20
minutes after second-line study drug administration, improved responsiveness to verbal or noxious stimulation at
20 minutes after second-line agent study drug administration, and the presence of cardiovascular adverse events
(life-threatening hypotension or cardiac arrhythmia; censoring adverse events occurring after intubation). At the
time of intubation, the presence of clinical seizures was
right-censored after intubation such that patients who were
seizing and then intubated before the 20-minute assessment were considered to have clinically apparent seizures at
20 minutes. Similarly, the assessment of improved responsiveness was right-censored at the time of intubation,
and patients who were intubated before 60 minutes were
considered not to have improved responsiveness at 60
minutes. Specifying these variables in this manner was
intended as a conservative procedure to prevent overestimation of the eﬀect of baseline patient characteristics
and treatment factors at this stage.

Phase 4 late treatment response candidate covariates included
clinically apparent seizures at 60 minutes after second-line agent
study drug administration and responsiveness to verbal or noxious stimulation at 60 minutes. Patients met enrollment criteria
for continued seizures. As above, the presence of clinical seizures
was right-censored at the time of intubation such that patients
who were previously seizing and then intubated before the 60minute assessment were considered to have clinically apparent
seizures at 60 minutes. Similarly, responsiveness was rightcensored at the time of intubation, and patients who were
intubated before 60 minutes were considered not to have improved responsive at 60 minutes. Specifying these variables in
this manner was intended as a conservative procedure to prevent
overestimation of the eﬀect of baseline patient characteristics and
treatment factors at this stage.
Clinical Outcome
The clinical outcome evaluated in this analysis was the binary
occurrence of intubation after ESETT study drug initiation
within a 120-minute time window, prespeciﬁed to limit inclusion of intubation events temporally remote from the
measured covariates. To mitigate against recall bias, we evaluated treatment responses that were evaluated in real time
before the decision to intubate was made.
Statistical Analysis
The primary analysis was the multivariate association of endotracheal intubation with baseline patient characteristics, treatment
factors, and early recovery, available to providers at 4 phases in SE
management. A stepwise multiple logistic model was performed
in blocks according to information available at each of these 4
phases of care (phase 1–4). For each phase, variables were

Figure 1 Time to Intubation

One hundred seventeen (24.5%) patients met the prespecified analysis endpoint of endotracheal intubation
within 120 minutes of Established Status Epilepticus Treatment Trial (ESETT) study drug initiation (inset, red line), after
which events were censored (y-axis signifies the proportion
of participants free of endotracheal intubation). This prespecified time point captured treatment events proximal to
the measured covariates while capturing 84.2% of the 139
patients undergoing endotracheal intubation over the 24
hours during which events were recorded.

e2376
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Figure 2 Individual or Combinations of Baseline Vital Signs Do Not Differentiate Which Patients Undergo Subsequent ETI

(A) Individual baseline vital signs are shown as overlapping violin plots for variables including heart rate (HR), respiratory rate (RR), systolic blood pressure
(SBP), diastolic blood pressure (DBP), and oxygen saturation (SaO2). Violin plots depict symmetric kernel densities around a common vertical axis, where the
kernel density estimated the probability density function at each point, providing a continuous analog of the univariate histogram. (B) Multivariable
combinations of baseline vital signs are displayed as colored contour plots depicting clusters of 3 vital signs (x, y, and color) represented 2-dimensionally as
individual patients (black dots). There is nearly complete overlap in baseline vital signs between the population of patients managed with and without
subsequent intubation, with differences driven primary by individual patient outliers presenting with the combination of multiple baseline vital sign
abnormalities (e.g., tachypnea, tachycardia, and a third abnormal vital sign; black circles) or the rare and isolated occurrence of profound hypoxia (red circle).
Contour lines computed with Delaunay triangulation separated distinct bivariate combinations of standardized vital signs, assigning a color for the representative value of a third standardized vital sign for the subpopulation of patients between contour lines. All vital signs are standardized as age-specific z
scores. ETI = endotracheal intubation.

selected for the ﬁnal models via Akaike informationcriterion–
optimal variable selection in each iteration of 3-fold crossvalidation. Before ﬁtting of the multiple logistic model for phase 1,
missing baseline data were imputed sequentially for each missing
variable, assuming a joint distribution for the variables, using a
Neurology.org/N

fully conditional speciﬁcation regression approach with all other
baseline (phase 1) covariates in the model and performing 20
burn-in iterations and a single imputed dataset. Features selected
during multivariate logistic regression at each phase of the model
and demonstrating a signiﬁcant independent association with
Neurology | Volume 96, Number 19 | May 11, 2021
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Table 2 Multiple Logistic Regression Models Associated With Intubation at Each Phase in the Continuum of SE
Management (n = 478)
Model Covariates
aOR (95% CI)

Whole Model (n = 478)
p Value

Phase 1 model: baseline patient characteristics
Age (odds per 5-y increase)

1.10 (1.04–1.17)

0.002

Hispanic ethnicity

0.47 (0.23–0.97)

0.04

Unprovoked (reference)

—

0.04

Febrile illness

1.56 (0.82–2.96)

Other

0.50 (0.22–1.14)

ASM nonadherence

0.69 (0.31–1.52)

Toxic (alcohol, drug withdrawal, poisoning)

1.68 (0.69–4.09)

Idiopathic

1.37 (0.48–3.88)

Stroke/hemorrhage

2.17 (0.72–6.58)

CNS tumor

1.33 (0.28–6.26)

CNS infection

2.90 (0.59–14.4)

Metabolic abnormality

5.77 (0.91–36.7)

AUC

R2 Value

0.63

0.12

0.0002

0.70

0.21

<0.0001

0.88

0.50

<0.0001

p Value

Acute precipitant

Total baseline LZPE in mg/kg (odds/0.1 mg/kg)

1.37 (1.04–1.81)

0.03

Baseline diastolic blood pressure, |z-score|, mean (SD)

1.35 (0.97–1.87)

0.07

Phase 1 and 2 model incorporating acute treatment factors
Age (5-y increase)

1.09 (1.02–1.17)

0.007

Hispanic ethnicity

0.54 (0.25–1.15)

0.11

Acute precipitant

0.04

Total baseline lorazepam equivalents (0.1 mg/kg increase)

1.41 (1.04–1.90)

0.03

Baseline diastolic blood pressure, |z-score|, mean (SD)

1.39 (0.98–1.97)

0.06

First quartile (reference)

—

0.0002

Second quartile

2.79 (1.16–6.71)

Third quartile

4.13 (1.80–9.46)

Fourth quartile (high risk)

8.12 (3.08–21.4)

Site-specific risk

Study drug allocation
LEV

1.35 (0.75–2.42)

FOS

2.05 (1.13–3.70)

VPA (reference)

—

0.053

Door-to-drug time (10-min increase)

0.98 (0.96–1.01)

0.22

Additional benzodiazepines within 20 mina

1.96 (0.82–4.67)

0.13

Phase 1, 2, and 3 model incorporating 20-min recovery
Site-specific risk
First quartile (reference)

—

<0.0001
Continued
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Table 2 Multiple Logistic Regression Models Associated With Intubation at Each Phase in the Continuum of SE
Management (n = 478) (continued)
Model Covariates
aOR (95% CI)
Second quartile

4.66 (1.62–13.4)

Third quartile

10.5 (3.70–29.5)

Fourth quartile (high risk)

23.4 (6.99–78.3)

Clinically apparent seizures at 20 mina
Improving responsiveness to stimulation at 20 mina
a

Hypotension/arrhythmia, within 120 min

Whole Model (n = 478)
p Value

5.95 (3.39–10.5)

<0.0001

0.09 (0.04–0.20)

<0.0001

13.8 (2.49–76.8)

0.003

Phase 1, 2, 3, and 4 model incorporating 60-min recovery

AUC

R2 Value

p Value

0.98

0.78

<0.0001

Site-specific risk
First quartile (reference)

—

Second quartile

2.81 (0.85–9.37)

Third quartile

7.95 (2.36–26.8)

Fourth quartile (high risk)
Improving responsiveness to stimulation at 20 min

0.001

14.7 (3.20–67.5)
a

0.20 (0.07–0.60)

0.004

Clinically apparent seizures at 60 mina

51.0 (20.4–128)

<0.0001

Improving responsiveness to stimulation at 60 mina

0.14 (0.05–0.43)

0.0006

Abbreviations: aOR = adjusted OR; ASM = antiseizure medication; AUC = area under the receiver operating curve; CI = confidence interval; FOS = fosphenytoin;
LEV = levetiracetam; LZPE = lorazepam equivalents; SE = status epilepticus; VPA = valproic acid.
Preintubation.

a

intubation were carried forward as candidates for feature
selection at subsequent phases (but not forced in as variables
at subsequent phases). The R2 and area under the receiver
operating curve (AUC) for the computed model at each
phase were reported in addition to the multivariate-adjusted
odds ratio (aOR) and 95% CI for variables meeting criteria
for inclusion within each phase. This process was repeated to
calculate all 4 models representing each phase of care.
Bivariable and multivariable analyses were performed with
SAS version 9.4; ﬁgures were generated with SAS version 9.4
or JMP Pro 15.0.0 (SAS Institute Inc, Cary, NC). Bivariate p
values for binary variables were calculated from the χ 2 test or
Fisher exact test and from the Wilcoxon rank-sum test for
nonparametric measures in exploratory analyses.
In exploratory analyses, we ﬁrst examined the association
between individual or combinations of baseline vital signs
(standardized as z scores) and the occurrence of intubation
within 120 minutes of study drug initiation. Second, we explored the association between site-speciﬁc variation in intubation rates and unique characteristics of these sites. To
evaluate for the presence of outliers, we assessed for those
sites in which the variation in intubation rate exceeded 95%
and 99% CIs according to enrollment volume. We speciﬁcally
examined for an association between age group and intubation rate, stratiﬁed by presentation to a dedicated adult,
Neurology.org/N

dedicated pediatric, or general emergency department. We in
addition examined association between site-speciﬁc variation
in intubation rates and baseline benzodiazepine dosing (total
lorazepam equivalents, milligrams per kilogram) and subsequent length of stay, restricting these analyses to sites enrolling at least 15 participants. Third, among patients
undergoing intubation, we measured the bivariate association
between the prospectively documented reason for intubation
and age both as a continuous variable and across the age
groups in which eﬃcacy was previously examined within the
ESETT cohort (2–17, 18–65, and >65 years).18 Finally, we
examined the unadjusted association between intubation and
discharge outcomes, including the odds of requiring admission to an intensive care unit (ICU), the mean diﬀerence in
ICU and hospital lengths of stay, the odds of discharge within
30 days, and the odds of all-cause in-hospital mortality.
Data Availability
A complete deidentiﬁed dataset, including individual participant data and a data dictionary deﬁning each ﬁeld in the
dataset, will be made available within 1 year after publication
of the primary ESETT results. Dataset requests using the
National Institute of Neurological Disorders and Stroke Data
Request Form should be sent to the National Institute of
Neurological Disorders and Stroke Clinical Research Liaison
(CRLiaison@ninds.nih.gov).
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Figure 3 Site-Specific Variation and Rate of ETI

(A, funnel plot) Risk of endotracheal intubation (ETI) includes outliers when adjusted for site enrollment volume. (B) Risk of intubation was significantly lower in
pediatric patients than adults but not significantly different when adults or children specifically presented to a center with dedicated pediatric, dedicated
adult, or mixed population. (C and D) Among (C) pediatric sites or (D) adult and general emergency department (ED) sites enrolling at least 15 participants, a
wide range of site-specific intubation rates were evident, but there was no clear site-specific association between the rate of intubation and the distribution of
total weight-standardized lorazepam (LZP) equivalents, intensive care unit (ICU), length of stay (LOS), or hospital LOS. Distributions are shown as violin plots of
equal area; white lines represent medians, and shaded boxes represent interquartile ranges. To examine associations between weight-based dosing and sitespecific intubation rates, this exploratory analysis restricted the analysis of high-enrolling pediatric ED sites to individuals weighing <40 kg, and at adult and
general ED sites to individuals weighing ≥40 kg. CI = confidence interval.
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Figure 4 Age and Length of Stay Vary According to the Reason for ETI

(A and B) Reason for endotracheal intubation (ETI) varied across age groups. Respiratory depression was the most commonly cited reason among patients 2
to 17 years of age (10%, n = 45) but the least commonly cited reason among patients >65 years of age (2%, n = 17). Decreased level of consciousness (LOC) and
continued seizure activity were more commonly cited as reasons for endotracheal intubation among patients 18 to 65 or >65 years of age compared with
patients 2 to 17 years of age. Patients intubated due to continued seizure activity (median 46 years, interquartile range [IQR] 17–65 years, p = 0.002) or
decreased LOC (median 42 years, IQR 7–64 years, p = 0.05) were significantly older (B) than patients intubated due to respiratory depression (median age 11
years, IQR 5–55 years). In addition, hospital length of stay was longer (C) for patients intubated due to continued seizure activity (median 7 days, IQR 3–12 days,
p = 0.04) than patients intubated due to respiratory depression (median length of stay 4 days, IQR 2–6.25 days).
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Results
Of 478 individuals meeting criteria for inclusion, 229 (47.9%)
were children <18 years of age and 53 (11.1%) were adults
>65 years of age. One hundred seventeen individuals (24.5%)
met the analysis endpoint of intubation within 120 minutes
(table 1), representing 84.2% of the 139 patients intubated
within the ﬁrst 24 hours (ﬁgure 1). At the 20-minute assessment, 32 participants (6.7%) had been intubated. At the 60minute assessment, 99 participants (20.7%) had been
intubated.
In the bivariate analyses (table 1), phase 1 baseline patient
characteristics signiﬁcantly associated with intubation included increasing age, Black race, non-Hispanic ethnicity, and
the precipitant of SE. Phase 2 acute treatment factors associated with intubation included quartile of site-speciﬁc intubation risk and randomization to FOS (compared to the
VPA reference group). Bivariate analysis demonstrated that in
addition to 20- and 60-minute measures of neurologic recovery, cardiovascular adverse events after study drug administration were signiﬁcantly associated with intubation. In a
post hoc analysis evaluating the inﬂuence of night and
weekend timing on intubation, we found no association of
intubation with a patient having presented during nighttime,
weekend, or nonbusiness hours.
Detailed analysis of baseline vital signs (ﬁgure 2) revealed
nearly complete overlap in the distribution of individual
baseline vital sign parameters between patients who were and
those who were not intubated (all p values not signiﬁcant), as
well as nearly complete overlap of multivariate clusters of
baseline vital signs between patients undergoing and those
not undergoing subsequent intubation, except for individual
outlier patients with the combination of tachypnea, tachycardia, and a third abnormal vital sign or alternatively the
singular occurrence of profound hypoxia (ﬁgure 2B).
In stepwise logistic regression (table 2), phase 1 baseline
characteristics that independently predicted intubation risk

included age, non-Hispanic ethnicity, acute precipitant, and
total weight-standardized lorazepam equivalents (AUC 0.63).
Baseline diastolic blood pressure met feature selection criteria
but was not signiﬁcantly associated with intubation. The
phase 2 model adding acute treatment factors as candidate
covariates to factors signiﬁcant in the phase 1 model demonstrated an increase in the model AUC for predicting intubation (0.70); in this model, age, acute precipitant, and
baseline weight-standardized lorazepam equivalents remained
signiﬁcantly associated with intubation, but non-Hispanic
ethnicity was no longer associated with intubation after
treatment factors entered the model. Of the treatment factors
entering the model at phase 2, site-speciﬁc risk of intubation
was the only covariate remaining signiﬁcant in the multivariate analysis. Baseline patient characteristics associated with
intubation risk did not explain the variation in site-speciﬁc
risk. Site-speciﬁc risk of intubation was also the only baseline
or treatment characteristic from phase 1 and phase 2 candidate covariates remaining in these models that adjusted for
20- and 60-minute neurologic recovery. Speciﬁcally, treatment at a site within the highest-quartile group of site-speciﬁc
intubation risk was associated with intubation in the phase 2
model including treatment factors (site-speciﬁc risk aOR 8.12,
95% CI 3.08–21.4) and in phase 3 (aOR 23.4, 95% CI
6.99–78.3) and phase 4 (aOR 14.7; 95% CI 3.2–67.5) models
adjusting for 20- and 60-minute neurologic recovery.
There was signiﬁcant site-speciﬁc variability in intubation
rates despite adjustment for enrollment volume (ﬁgure 3).
Intubation rates were overall lower in children than in adults,
but stratifying by age showed no diﬀerences in treatment at a
dedicated pediatric, dedicated adult, or general ED. Among
hospitals enrolling at least 15 patients, site-speciﬁc intubation
rates varied widely, ranging between 4% and 32% among
pediatric sites (analysis restricted to patients <40 kg) and
between 19% and 39% among adult and general emergency
department sites (analysis restricted to patients ≥40 kg).
Weight-standardized doses of total lorazepam equivalents
administered before study drug were greater and hospital
length of stay was shorter among pediatric patients than

Table 3 Unadjusted Associations Between Endotracheal Intubation and Discharge Outcomes
Intubation Status, 120 min After Randomization
Not Intubated (n = 361)

Intubated (n = 117)

OR or Mean Difference (95% CI)

p Value

a

<0.0001b

Admission to ICU, n (%)

175 (48%)

111 (95%)

19.7 (8.43 to 45.9)

Length of ICU stay, median (IQR), d

0 (0–2)

3 (2–5)

−2.9 (−4.0 to −1.8)c

<0.0001d

Length of hospital stay, median (IQR), d

2 (1–4)

5 (3–12)

−5.0 (−6.7 to −3.2)c

<0.0001d

Discharged from hospital within 30 d, n (%)

346 (96)

101 (86)

0.27 (0.13 to 0.57)a

<0.0001b

All-cause mortality, n (%)

7 (2)

5 (4)

2.26 (0.70 to 7.25)a

0.1772b

Abbreviations: CI = confidence interval; ICU = intensive care unit; IQR = interquartile range; OR = odds ratio.
a
Odds ratio.
b
Fisher exact test.
c
Mean difference.
d
Wilcoxon rank-sum test.
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adults, but there were no signiﬁcant associations between sitespeciﬁc intubation risk and benzodiazepine dosing or length
of stay.
The reason for intubation was ascertained among the 117
patients undergoing intubation within the ﬁrst 120 minutes
after study drug administration as respiratory depression in
41 (35.0%), decreased level of consciousness in 30 (25.6%),
and persistent seizure activity in 42 (35.9%) patients (ﬁgure
4). Four (3.4%) patients underwent intubation for other
cited reasons, including epistaxis, emesis, treatment of ictalinterictal continuum activity, and the combination of continued seizures and respiratory depression (1 each). Respiratory depression was the most common reason for
intubation among pediatric patients 2 to 17 years of age
(53%) but was the reason for intubation in only 29% of
patients 18 to 65 years of age and only 6% of patients >65
years of age. Alternatively, continued seizure activity was the
reason cited for intubation in 22% of pediatric patients 2 to
17 years of age but was more common among adults 18 to 65
years of age (40%) and adults >65 years of age (59%) (Fisher
exact test, p = 0.007). Overall, patients intubated for respiratory depression were signiﬁcantly younger (median age
11 years, interquartile range [IQR] 5–55 years) than patients
intubated for decreased level of consciousness (median 42
years, IQR 7–64 years, p = 0.05) or continued seizure activity
(median 46 years, IQR 17–65 years, p = 0.002). In addition,
patients intubated for respiratory depression had a signiﬁcantly shorter hospital length of stay (median length of stay 4
days, IQR 2–6.25 days) than patients intubated for continued seizure activity (median 7 days, IQR 3–12 days, p =
0.04), although duration of intubation itself was not collected as a primary data variable.
Unadjusted associations between intubation and discharge
outcomes (table 3) demonstrated that patients intubated in
the initial 120 minutes were more likely to be admitted to
the ICU (odds ratio 19.7, 95% CI 8.43–45.9) and less likely
to be discharged from the hospital within 30 days (odds
ratio 0.27, 95% CI 0.13–0.57). Median ICU length of stay
was brief for all patients: 3 days (IQR 2–5 days) for patients
intubated and 0 days (IQR 0–2 days) for those who were
not intubated (mean diﬀerence 2.9 days, 95% CI 1.8–4.0).
Median hospital length of stay was also longer for patients
intubated (5 days, IQR 3–12 days) than those who were not
intubated (2 days, IQR 1–4 days; mean diﬀerence 5.0 days,
95% CI 3.2–6.7). There was no signiﬁcant diﬀerence in allcause hospital mortality, although mortality rates were low
in both groups.

Discussion
In this secondary analysis of a large randomized comparative eﬀectiveness trial of 3 antiseizure medications for
benzodiazepine-refractory SE, baseline patient characteristics
including age, ethnicity, acute precipitant, baseline vital signs,
Neurology.org/N

and baseline benzodiazepine dosing were only weakly associated with endotracheal intubation. At the treatment phase
and beyond, site-speciﬁc diﬀerences in intubation rates had a
strong, independent association, even after adjustment for
lack of early neurologic recovery. This eﬀect was present
despite lack of neurologic recovery being deﬁned conservatively, in order to avoid overestimating eﬀects of phase 1
baseline and phase 2 treatment factors. Site-speciﬁc outliers
were identiﬁed after adjustment for enrollment, including sitespeciﬁc intubation rates ranging from 4% to 32% at pediatric
centers and 19% to 39% among adult centers with high enrollment. While older age was associated with intubation risk,
designation as a dedicated pediatric, adult, or general ED site
or benzodiazepine dosing did not clearly explain site-speciﬁc
variation, nor did enrollment volume, door-to-drug time,
benzodiazepine dosing, or length of stay as a proxy of disease
severity.
It is not possible to determine from these analyses the causes
of site-speciﬁc variation intubation risk. Unmeasured clinical
factors such as baseline comorbid conditions also may have
aﬀected the decision to perform intubation, given that intubation rate was associated with the acute precipitant of SE.
Finally, unmeasured structural factors such as the transport
distance from a site’s emergency department to the admitting
unit or neuroimaging may explain this variation. Because sitespeciﬁc variation was associated with intubation risk independently of covariates recorded in this clinical trial, future
studies, including qualitative research, are required to determine whether site-speciﬁc risk is attributable predominantly to unmeasured clinical, structural, or practitioner
factors. Trends in intubation rates among patients with SE
have increased markedly over time,16 underscoring that
practitioner approach may explain part of this site-speciﬁc
variation. Of note, trends in intubation rates have decreased
for other conditions over time, including stroke, profound
agitation, and elective surgery,23-25 although intubation rates
vary with patient and provider variability in these other conditions as well,23,24,26-28 in some populations with associated
interactions with outcome.29
Of note, allocation in ESETT to FOS was associated with an
increased risk of intubation when adjusted for several baseline
and treatment factors, including age as a continuous variable.
The increased rate of intubation among patients receiving FOS
raises the consideration of LEV and VPA as preferable secondline agents, particularly in pediatric patients ≥2 years of age.18
However, other large randomized trials have not found similar
associations.13,30 Early neurologic recovery variables, including
seizure cessation and improved responsiveness at 20 minutes,
were also strongly associated with intubation risk, but sitespeciﬁc heterogeneity was the strongest risk factor.
There were no strong bivariate associations between the decision
to perform intubation and individual baseline vital signs, nor did
combinations of multiple baseline vital signs discriminate baseline physiologic phenotypes associated with the risk of
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subsequent intubation. While continuous physiologic data were
not recorded, speciﬁc adverse events of life-threatening hypotension or arrhythmia during the phase of assessing early neurologic recovery phase were independently associated with
subsequent intubation. Still, site-speciﬁc risk was associated with
intubation independently of such adverse cardiac events.
Limitations in this study include ascertainment of covariates
by the study team or care providers who were not blinded to
the outcome; this potential for recall bias is mitigated by
treatment response being evaluated in real time before the
decision to intubate was made. Second, while site-speciﬁc risk
itself was not associated with other signiﬁcant baseline characteristics such as seizure precipitant or ethnicity, we did not
have available additional data for which site may have served
as a proxy, including socioeconomic status or type of insurance. In addition, the acute precipitant of SE was determined by adjudication after hospital discharge; while this
information may not always have been known at admission,
the highest-risk conditions—metabolic disturbances, stroke,
intracerebral hemorrhage, neurologic infections, brain tumors, and toxic exposures—are often diagnosed early after
presentation for many patients. Finally, we examined only
associations between intubation and outcomes in bivariate
models, demonstrating that these associations are similar to
associations previously demonstrated.31-34
By quantifying the contribution of practice variation and
treatment response on the risk of intubation, our results
suggest that the inﬂuence of age and site-speciﬁc practice
variation on the decision to perform intubation may exceed
the inﬂuence of door-to-drug time or second-line agent
choice. Data from the 20- and 60-minute phases of neurologic
recovery in addition underscore previous observations that
terminating seizures is associated with reduced rates of intubation, independently of benzodiazepine dosing.35 Accordingly, the association itself between total benzodiazepine
dosing and intubation is likely the result of confounding by
indication, in which the continued occurrence of seizures,
itself a risk for subsequent intubation, requires additional
doses of benzodiazepines.
Clinically, these results point to opportunities to study the
clinical impact of reducing practice variation, for example, by
promoting noninvasive airway management strategies.36
Considering that the vast majority of ESETT trial patients
lacked baseline vital sign abnormalities, one strategy deserving
future evaluation is managing mild initial respiratory depression with basic airway maneuvers before proceeding to
intubation. The American Epilepsy Society guidelines recommend interventions stabilizing the airway and breathing in
the ﬁrst 5 minutes by prehospital or emergency personnel, but
the potential remains to clarify the continued approach to the
airway at later phases of care during neurologic recovery.35

with SE may be inﬂuenced by our ﬁndings. First, without
clinical standardization guidelines aimed at minimizing
heterogeneity, variability in intubation practice patterns
may obscure signiﬁcant diﬀerences between interventions
for SE. Second, intubation risk appears to be driven more
by continued seizures and failure to show improving responsiveness than by administration of additional benzodiazepines, suggesting that future trials exploring more
intensive early therapy for SE may be warranted. Third,
patients undergoing intubation, particularly those intubated for respiratory depression, have a relatively short
length of stay and a low mortality rate despite higher rates
of precipitants including acute brain injuries, tumors, and
infections, suggesting that intubation performed for
transport, neuroimaging, or progression of an acute brain
injury may not itself represent treatment failure.
Both clinical practice and the design of clinical trials testing
candidate therapies for SE may beneﬁt from the emergence
of rapid EEG monitoring technologies.37 These tools allow
emergency practitioners to diﬀerentiate patients with depressed level of consciousness who are intubated for airway
protection from those intubated for continued seizure activity by directly measuring the neurophysiologic response
to treatment.38 In future clinical trials, novel endpoints
incorporating an ordinal “desirability of outcome” ranking39 may allow testing the tradeoﬀ between seizure cessation and intubation related to lack of clinical or
neurophysiologic improvement. These and other strategies
may more precisely deﬁne the eﬃcacy of seizure cessation
by identifying more biologically based surrogates of clinical
outcome.13,17,18,30
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